venetoclax
Selected indexed studies
- Venetoclax-based therapies for acute myeloid leukemia. (Best Pract Res Clin Haematol, 2019) [PMID:31203996]
- First-Line Venetoclax Combinations in Chronic Lymphocytic Leukemia. (N Engl J Med, 2023) [PMID:37163621]
- Venetoclax in adult acute myeloid leukemia. (Biomed Pharmacother, 2023) [PMID:37925935]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Venetoclax synergizes with gilteritinib in FLT3 wild-type high-risk acute myeloid leukemia by suppressing MCL-1. (2022) pubmed
- Venetoclax-based therapies for acute myeloid leukemia. (2019) pubmed
- First-Line Venetoclax Combinations in Chronic Lymphocytic Leukemia. (2023) pubmed
- Venetoclax in adult acute myeloid leukemia. (2023) pubmed
- Venetoclax-Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia. (2018) pubmed
- Venetoclax: a new player in the treatment of children with high-risk myeloid malignancies? (2024) pubmed
- Venetoclax enhances T cell-mediated antileukemic activity by increasing ROS production. (2021) pubmed
- Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trial. (2020) pubmed
- Targeting Mitochondrial Structure Sensitizes Acute Myeloid Leukemia to Venetoclax Treatment. (2019) pubmed
- Sonrotoclax overcomes BCL2 G101V mutation-induced venetoclax resistance in preclinical models of hematologic malignancy. (2024) pubmed